USPTO Examiner ALAWADI SARAH - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18402953ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONSJanuary 2024December 2025Allow2310NoNo
18392013COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERSDecember 2023December 2025Abandon2410NoNo
18392008COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDERDecember 2023December 2025Abandon2410NoNo
18543203ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROLDecember 2023September 2025Allow2131NoNo
18532876METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEXDecember 2023November 2025Allow2420NoNo
18386758METHOD OF TREATING A GLAZED CERAMIC ARTICLENovember 2023April 2025Allow1800NoNo
18492136MATERIALS AND METHODS FOR THE CONTROL OF NEMATODESOctober 2023July 2025Allow2111NoNo
18381436TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSOctober 2023December 2025Allow2610NoNo
18286914NANOPARTICULATE COMPOSITIONSOctober 2023October 2025Allow2400YesNo
18379598Botanical Film-Forming Acne CompositionsOctober 2023June 2025Allow2010NoNo
18457668SILICONE INFUSED WITH SILVERAugust 2023August 2025Abandon2311NoNo
18233535MULTIPLE USE WOUND AND HEALING CREAMAugust 2023March 2026Abandon3101NoNo
18216663PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETESJune 2023February 2026Allow3131NoNo
18330238ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEJune 2023November 2025Abandon3010NoNo
18254284ANTIPERSPIRANT COMPOSITIONSMay 2023February 2026Abandon3210NoNo
18251645ANTISEPTIC COMPOSITIONMay 2023March 2026Allow3410YesNo
18133349AQUEOUS FORMULATIONS OF TOPIRAMATEApril 2023February 2025Allow2231NoNo
18296270MACROGOL 15 HYDROXYSTEARATE FORMULATIONSApril 2023April 2025Abandon2401NoNo
18022018Therapeutic And Cosmetic Wound TreatmentFebruary 2023March 2026Abandon3711NoNo
18041419AN AEROSOL COMPOSITION FOR ELIMINATING PATHOGENIC MICROORGANISMSFebruary 2023November 2025Abandon3301NoNo
18107788PERACETIC ACID ANTIMICROBIAL COMPOSITION SYSTEM AND METHODFebruary 2023January 2025Abandon2321NoNo
18167056FORMULATIONS OF PILOCARPINE AND BRIMONIDINE COMPOUNDS AND RELATED METHODSFebruary 2023August 2024Allow1830NoNo
18017296DISINFECTING, SKIN-TOLERABLE, SUPERFATTING CARE AGENT FOR APPLICATION TO THE SKINJanuary 2023March 2026Abandon3810NoNo
18003174Hydrophilic Degradable Microspheres for Local Delivering of Glycopeptide Antibiotics and Polycationic Peptide AntibioticsDecember 2022December 2025Abandon3601NoNo
18086679ANTISEPTIC COMPOSITIONSDecember 2022December 2024Allow2441YesNo
17980256TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSNovember 2022October 2023Allow1110YesNo
17965253COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDOctober 2022February 2023Allow400YesNo
17954703COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDSeptember 2022January 2024Abandon1610NoNo
17931139METHOD FOR THE TREATMENT OF VIRAL INFECTIONSSeptember 2022January 2026Abandon4001NoNo
17905867MEDICINE LOADED NANO-CAPSULE ADDITIVE PMMA CEMENTSeptember 2022October 2025Abandon3810NoNo
17897666METHOD FOR DISINFECTION OF ITEMS AND SPACESAugust 2022July 2023Allow1110NoNo
17799871EXOGENOUS NITRIC OXIDE FOR IMPROVED SUSCEPTIBILITY AND LOWERED ANTIBIOTIC RESISTANCE IN RESISTANT RESPIRATORY BACTERIAAugust 2022January 2026Abandon4101NoNo
17799543HUMAN CD47-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOFAugust 2022June 2025Allow3410NoNo
17819076PHARMACEUTICAL OPHTHALMIC COMPOSITIONSAugust 2022February 2023Allow600NoNo
17882334Therapeutic Gas Microfoam for Skin RecoveryAugust 2022October 2024Abandon2611NoNo
17877701HAND SANITIZER MICROEMULSIONJuly 2022July 2024Abandon2311NoNo
17796584ANTIOXIDANT OR SKIN STRESS INHIBITORJuly 2022March 2026Abandon4301NoNo
17859692ANTIBIOTIC COMPOSITION COMPRISING A COMPOSITE OF DIATOMACEOUS EARTH AND ZINC OXIDE, AND COMBINATION PREPARATION WITH THE SAMEJuly 2022March 2026Allow4420NoNo
17859040ANTIPERSPIRANT COMPOSITIONSJuly 2022June 2024Abandon2320NoNo
17842689IMPLANTABLE PHARMACEUTICAL COMPOSITION PREPARED FROM COMPONENTS CONSISTING OF CALCIUM SULFATE ALPHA-HEMIHYDRATE, VANCOMYCIN AND GENTAMICINJune 2022July 2024Allow2521YesNo
17784839DEODORIZING COMPOSITIONJune 2022September 2025Abandon4001NoNo
17783889Antimicrobial CompositionJune 2022December 2025Abandon4210NoNo
17836597TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSJune 2022October 2024Allow2830NoNo
17831705ANTIMICROBIAL AGENT AND ANTIMICROBIAL RESIN COMPOSITION COMPRISING THE SAMEJune 2022June 2025Allow3731YesNo
17738037pH/CO2-RESPONSIVE SMART ANTI-PATHOGEN COATINGS THAT CONTROL, REPEL, AND/OR INACTIVATE VIRUSES AND BACTERIAMay 2022May 2024Abandon2511NoNo
17736443METHODS FOR INHIBITING PATHOGENIC INFECTION AND INHIBITING GROWTH OF PATHOGENSMay 2022December 2025Allow4351NoNo
17657508COMPOSITIONS FOR PREVENTION AND TREATMENT OF RSV AND CORONAVIRUS INFECTIONMarch 2022January 2025Abandon3341YesNo
17704653COMPOSITION FOR CONTROLLING INDIGENOUS BACTERIAL FLORA IN THE SKINMarch 2022March 2025Allow3621YesNo
17691532SINGLE CHAIN FUSIONCONSTRUCTS COMPRISING MULTIMERIC ANTIBODY FRAGMENTS FUSED TO COLLAGEN TRIMERIZATION DOMAINSMarch 2022June 2025Allow3900NoNo
17688915ANTIMICROBIAL BIOCOMPATIBLE CO-DOPED MAGNESIUM OXIDE NANOCOMPOSITE COMPOSITIONSMarch 2022September 2023Allow1811NoNo
17637104ANTISEPTIC APPLICATIONS OF METAL NANOPARTICLE AGGLOMERATESFebruary 2022September 2025Allow4341NoYes
17583738Praziquantel FormulationsJanuary 2022April 2025Allow3832YesNo
17570957POWDER FORMULATION FOR INGREDIENT DISPERSIONJanuary 2022December 2024Abandon3521NoNo
17557135ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROLDecember 2021September 2023Allow2111YesNo
17542838OCULAR INSERT COMPOSITION OF A SEMI-CRYSTALLINE OR CRYSTALLINE PHARMACEUTICALLY ACTIVE AGENTDecember 2021August 2023Abandon2101NoNo
17535556Sunscreen CompositionsNovember 2021September 2024Abandon3421NoNo
17609887RANDOM COPOLYMER STABILIZED NANOPARTICLES ENCAPSULATING SOLUBLE HYDROPHILIC COMPOUNDSNovember 2021May 2025Abandon4230NoNo
17521198Orally Administrable CompositionNovember 2021December 2023Abandon2510NoNo
17517905MATERIALS AND METHODS FOR THE CONTROL OF NEMATODESNovember 2021August 2023Allow2101YesNo
17506476STABLE ANHYDROUS DISINFECTANT CONCENTRATE FORMULATION AND METHOD OF MAKING THE SAMEOctober 2021October 2024Abandon3621NoNo
17499374ANTIMICROBIAL COATING FOR FOOD CONTACT SURFACESOctober 2021February 2026Abandon5211NoNo
16974374CHEMICAL FORMULATIONS AND THEIR USE IN NEUTRALIZING OR ELIMINATING ODORSSeptember 2021June 2025Abandon4641NoNo
17463654USE OF AN ANTIMICROBIAL COMPOSITIONSeptember 2021July 2023Abandon2201NoNo
17458674STABLE ORAL LIQUID COMPOSITION OF TERAZOSINAugust 2021July 2025Allow4761YesNo
17410613ANTIMICROBIAL BLADDER ADDITIVES SYSTEM AND METHODAugust 2021October 2023Abandon2611NoNo
17387196LONG-WEARING COSMETIC COMPOSITION COMPRISING EXPANDED PERLITEJuly 2021January 2026Abandon5461NoNo
17381445ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONSJuly 2021September 2023Allow2611YesNo
17364386SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTIONJune 2021October 2025Allow5210NoNo
17312551MICROBIOSTATIC SOAP THAT REDUCES THE TRANSMISSION OF MICROBESJune 2021June 2024Abandon3621NoNo
17311561OCULAR HYDROGEL COMPOSITIONSJune 2021February 2026Abandon5641NoNo
17287105COMPOSITIONS FOR ADMINISTRATION TO RUMINANT ANIMALSApril 2021November 2024Abandon4320NoNo
17223124DRUG DELIVERY SYSTEMApril 2021March 2024Abandon3620NoNo
17216341METHODS OF ADMINISTERING ANIONIC CANNABINOIDS DISSOLVED IN WATERMarch 2021July 2023Abandon2810NoNo
17279812ANTIMICROBIAL MIXTURES COMPRISING AT LEAST ONE HYDROXYPHENONE DERIVATIVEMarch 2021September 2024Allow4221YesNo
17203429MACROGOL 15 HYDROXYSTEARATE FORMULATIONSMarch 2021July 2023Abandon2801NoNo
17178692BOTANICAL FILM-FORMING ACNE COMPOSITIONSFebruary 2021July 2023Abandon2920NoNo
17267024ABSORBABLE BONE WAX AND PREPARATION METHOD THEREOFFebruary 2021October 2023Allow3200YesNo
17165754COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDFebruary 2021August 2024Abandon4241YesYes
17163848STABLE ORAL LIQUID COMPOSITION OF TERAZOSINFebruary 2021September 2021Allow711YesNo
17146662SYNERGISTIC METHODS OF USING BENZOXABOROLE COMPOUNDS AND PRESERVATIVE GASES AS AN ANTIMICROBIAL FOR CROPSJanuary 2021September 2024Allow4421NoNo
17146128HYPOCHLORITE BASED HARD SURFACE DISINFECTANTSJanuary 2021May 2025Allow5250YesNo
17120856PRODUCTDecember 2020May 2024Abandon4101NoNo
16972008LOW GLYCEMIC COMPOSITION AND METHODS OF MAKING AND USING THEREOFDecember 2020May 2024Abandon4101NoNo
17059428MILD COMPOSITION FOR USE IN TOPICAL TREATMENT OF SKIN AND NAIL DISORDERS CAUSED BY VIRUS AND FUNGUSNovember 2020April 2024Abandon4121NoNo
17084514PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOFOctober 2020July 2022Allow2110NoNo
17083232PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOFOctober 2020October 2022Allow2300NoNo
17077897OXYGENATED SKIN LOTIONOctober 2020October 2023Abandon3611NoNo
17077969COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDOctober 2020January 2025Abandon5180YesNo
17070365ANTIMICROBIAL COMBINATIONS SYSTEM AND METHODOctober 2020December 2023Abandon3821NoNo
17067676ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEOctober 2020July 2023Abandon3310NoNo
17067259TOPICAL FORMULATIONS COMPRISING STRONTIUM AND METHYLSULFONYLMETHANE (MSM) AND METHODS OF TREATMENTOctober 2020October 2023Allow3631YesNo
17060121Antibacterial and Non-Clumping Liquid SprayOctober 2020January 2023Abandon2720NoNo
17042473ANTIPERSPIRANT PRODUCTSSeptember 2020February 2024Abandon4110NoNo
17033294TREATMENT AND PROPHYLAXIS OF RADIATION DERMATITISSeptember 2020August 2023Allow3510YesNo
17040825SOLUTIONS COMPRISING OZONIZED OILSeptember 2020November 2023Abandon3701NoNo
16977048COMPOSITE PARTICLESAugust 2020October 2024Abandon4911NoNo
17001726Slow Release Calcium CompositionAugust 2020July 2021Allow1111YesNo
16991397Praziquantel FormulationsAugust 2020March 2022Abandon1931NoNo
16988387COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDAugust 2020February 2025Abandon5450NoNo
16941414COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDJuly 2020September 2020Allow200YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALAWADI, SARAH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
60
Examiner Affirmed
53
(88.3%)
Examiner Reversed
7
(11.7%)
Reversal Percentile
24.3%
Lower than average

What This Means

With a 11.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
121
Allowed After Appeal Filing
16
(13.2%)
Not Allowed After Appeal Filing
105
(86.8%)
Filing Benefit Percentile
16.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALAWADI, SARAH - Prosecution Strategy Guide

Executive Summary

Examiner ALAWADI, SARAH works in Art Unit 1619 and has examined 687 patent applications in our dataset. With an allowance rate of 36.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner ALAWADI, SARAH's allowance rate of 36.5% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALAWADI, SARAH receive 2.84 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALAWADI, SARAH is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by ALAWADI, SARAH. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.5% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.2% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 45.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 41% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 37.5% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 52.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.3% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.